Variances in the mRNA expression profile of TGF- β1-3 isoforms and its TGF-βRI-III receptors during cyclosporin a treatment of psoriatic patients.

Conclusions: The changes in expression profiles of TGF-β1-3 and TGF-βRI-III during CsA therapy can be a useful molecular marker of lost sensitivity to the medicine. PMID: 30429710 [PubMed] (Source: Advances in Dermatology and Allergology)

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2TmIhn8